Ascendis Pharma A/S (ASND)
| Bid | 120.13 |
| Market Cap | 9.31B |
| Revenue (ttm) | 363.64M |
| Net Income (ttm) | -378.08M |
| EPS (ttm) | -7.16 |
| PE Ratio (ttm) | -21.73 |
| Forward PE | -35 |
| Analyst | Buy |
| Ask | 178 |
| Volume | 395,927 |
| Avg. Volume (20D) | 504,667 |
| Open | 152.53 |
| Previous Close | 150.99 |
| Day's Range | 151.01 - 159.14 |
| 52-Week Range | 111.09 - 169.37 |
| Beta | 0.54 |
About ASND
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops Tra...
Analyst Forecast
According to 14 analyst ratings, the average rating for ASND stock is "Buy." The 12-month stock price forecast is $196, which is an increase of 25.95% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 hour ago · accessnewswire.com
Ascendant Resources Notifies Shareholders Of Upcoming Special MeetingTORONTO, ON / ACCESS Newswire / April 14, 2025 / Further to its press release on February 3, 2025, Ascendant Resources Inc. (the "Company" or "Ascendant") (TSX:ASND) announces that it has mailed and f...
2 months ago · accessnewswire.com
Ascendant Resources Announces Closing of First Tranche of Private Placement• Funds to Progress Lagoa Salgada Project and extinguish a significant portion of short-term payables • Additional Support Received for Arrangement with Cerrado NOT FOR DISTRIBUTION TO U.S. NEWS WIRE ...
